Company Filing History:
5 out of 8 
2 out of 8 
1 out of 3 Years Active: 2015-2020
Title: Kurt Schönfeld: Innovator in Cancer Immunotherapy
Introduction
Kurt Schönfeld is a prominent inventor based in Langen, Germany. He has made significant contributions to the field of cancer immunotherapy, holding a total of 7 patents. His work focuses on the development of innovative therapeutic approaches that harness the power of the immune system to combat cancer.
Latest Patents
One of Schönfeld's latest patents is titled "Chimeric antigen receptors with an optimized hinge region." This invention relates to multi-functional proteins that include a signal peptide, a target-specific recognition domain, a linker region, and an effector domain. The proteins are designed to generate target-specific effector cells for use as a medicament, particularly in cancer treatment and adoptive immunotherapy. Another notable patent is "Interleukin 15 as selectable marker for gene transfer in lymphocytes." This invention utilizes interleukin-15 as a selectable marker for gene transfer into mammalian cells, particularly for therapeutic applications in cancer and immunotherapy.
Career Highlights
Kurt Schönfeld has worked with esteemed organizations such as the Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus. His research has significantly advanced the understanding and application of chimeric antigen receptors in cancer treatment.
Collaborations
Throughout his career, Schönfeld has collaborated with notable colleagues, including Winfried Wels and Christiane Knopp. These partnerships have contributed to the development of innovative therapeutic strategies in the field of immunotherapy.
Conclusion
Kurt Schönfeld's contributions to cancer immunotherapy through his patents and collaborations highlight his role as a leading inventor in the field. His work continues to pave the way for new therapeutic options in the fight against cancer.